Chemical Structure (01)
Abiraterone Acetate Tablet, Film Coated
Product Images NDC 60505-4764
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Abiraterone Acetate (NDC 60505-4764). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Apotex Corp., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (02)
Figure 2 (03)
This appears to be a chart or graph showing the number of subjects without death over a period of time. The data compares the effectiveness of Abiraterone Acetate and a placebo. Abiraterone Acetate seems to have had higher survival rates than the placebo over time.*
Figure 3 (04)
The text seems to be a table showing the percentage of subjects without radiographic progression after receiving either Abiraterone Acetate or a Placebo. The table includes the number of subjects for each treatment group and the time frame of 24 months from randomization. The last row shows the percentage difference between subjects on Abiraterone Acetate and those on Placebo.*
Figure 4 (05)
Principal Display Panel (500 mg Tablet Bottle Label)
This is a medication for which the usual dosage is specified in the package insert. The medication contains abiraterone acetate and is manufactured by Qilu Pharmaceutical for Apotex Corp. The tablets should not be crushed or chewed and should be kept out of reach of children. Each film-coated tablet contains 500 mg of abiraterone acetate, USP. The available quantity is 60 film-coated tablets.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
